Improved immunogenicity against a Her2/neu-Derived peptide by employment of a Pan HLA DR-Binding epitope and CpG in a BALB/c mice model
S Tahaghoghi-Hajghorbani… - Anti-Cancer Agents …, 2017 - ingentaconnect.com
Background: An efficient strategy to improve the immunogenicity of peptide vaccines is the
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …
Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model
S Tahaghoghi-Hajghorbani… - Anti-cancer agents …, 2017 - pubmed.ncbi.nlm.nih.gov
Background An efficient strategy to improve the immunogenicity of peptide vaccines is the
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …
Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model.
S Tahaghoghi-Hajghorbani… - Anti-cancer Agents in …, 2017 - europepmc.org
Background An efficient strategy to improve the immunogenicity of peptide vaccines is the
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …
use of a synthetic peptide containing cytotoxic T-lymphocyte (CTL) epitopes with T-helper …